Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Study to Evaluate The Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-alpha Inhibitors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs RO 7123520 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Roche
- 03 Apr 2022 This trial has been completed in Italy (Date of the global end of the trial : 06-Nov-2018), according to European Clinical Trials Database record.
- 17 Jan 2020 Status changed from completed to discontinued.
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.